HSP90AA1 and neoplasm: Thus, tumours such as adrenocortical carcinoma that naturally overexpress P-gp and exhibit appreciable resistance to 17-AAG are still susceptible to synthetic Hsp90 inhibitors such as BIIB021 [31].